{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:35:44Z","timestamp":1786599344470,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/mot.0b013e32834c23a7","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:59:20Z","timestamp":1317758360000},"page":"594-599","source":"Crossref","is-referenced-by-count":15,"title":["Our evolving understanding of late kidney allograft failure"],"prefix":"10.1097","volume":"16","author":[{"given":"Robert S.","family":"Gaston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210218","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM196306132682401","article-title":"Prolonged survival of human-kidney homografts by immunosuppressive drug therapy.","volume":"268","author":"Murray","year":"1963","journal-title":"N Engl J Med"},{"key":"R2-6-20210218","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal.","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transplant"},{"key":"R4-6-20210218","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1600-6143.2009.02943.x","article-title":"Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study.","volume":"10","author":"Matas","year":"2010","journal-title":"Am J Transplant"},{"key":"R5-6-20210218","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff 05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R6-6-20210218","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-6-20210218","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation.","volume":"346","author":"Pascual","year":"2002","journal-title":"N Engl J Med"},{"key":"R8-6-20210218","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity.","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-6-20210218","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00007890-197910000-00006","article-title":"Antithymocyte globulin in renal allograft recipients. Multicenter trials using a 14-dose regimen.","volume":"28","author":"Wechter","year":"1979","journal-title":"Transplantation"},{"key":"R11-6-20210218","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00007890-199101000-00011","article-title":"Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients.","volume":"51","author":"Barber","year":"1991","journal-title":"Transplantation"},{"key":"R12-6-20210218","first-page":"523","article-title":"Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments.","volume":"4","author":"Wood","year":"1972","journal-title":"Transplant Proc"},{"key":"R13-6-20210218","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation.","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-6-20210218","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/01.sla.0000089853.11184.53","article-title":"Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning.","volume":"238","author":"Shapiro","year":"2003","journal-title":"Ann Surg"},{"key":"R15-6-20210218","first-page":"204","article-title":"Studies in hyperacute and chronic renal homograft rejection in man.","volume":"62","author":"Williams","year":"1967","journal-title":"Surgery"},{"key":"R16-6-20210218","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000658-198502000-00003","article-title":"A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.","volume":"201","author":"Najarian","year":"1985","journal-title":"Ann Surg"},{"key":"R17-6-20210218","first-page":"17","article-title":"3rd, Iwatsuki S, et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation.","volume":"151","author":"Starzl","year":"1980","journal-title":"Surg Gynecol Obstet"},{"key":"R18-6-20210218","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors.","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"R19-6-20210218","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198409133111103","article-title":"Cyclosporine-associated chronic nephropathy.","volume":"311","author":"Myers","year":"1984","journal-title":"N Engl J Med"},{"key":"R20-6-20210218","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0140-6736(87)90233-9","article-title":"Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation.","volume":"1","author":"Morris","year":"1987","journal-title":"Lancet"},{"key":"R21-6-20210218","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"key":"R22-6-20210218","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ki.1988.38","article-title":"The long-term course of cyclosporine-associated chronic nephropathy.","volume":"33","author":"Myers","year":"1988","journal-title":"Kidney Int"},{"key":"R23-6-20210218","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1681\/ASN.V42214","article-title":"Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake.","volume":"4","author":"Elzinga","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"R24-6-20210218","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00007890-198707000-00027","article-title":"Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function.","volume":"44","author":"English","year":"1987","journal-title":"Transplantation"},{"key":"R25-6-20210218","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/ki.1997.380","article-title":"Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.","volume":"52","author":"Shihab","year":"1997","journal-title":"Kidney Int"},{"key":"R26-6-20210218","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ.","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R29-6-20210218","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.TP.0000144181.47045.FE","article-title":"A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results.","volume":"78","author":"Gallagher","year":"2004","journal-title":"Transplantation"},{"key":"R30-6-20210218","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.00052.x","article-title":"Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.","volume":"18","author":"Oberbauer","year":"2005","journal-title":"Transpl Int"},{"key":"R31-6-20210218","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.tp.0000258586.52777.4c","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.","volume":"83","author":"Flechner","year":"2007","journal-title":"Transplantation"},{"key":"R32-6-20210218","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1600-6143.2008.02307.x","article-title":"Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.","volume":"8","author":"Van Gurp","year":"2008","journal-title":"Am J Transplant"},{"key":"R33-6-20210218","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation.","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"R34-6-20210218","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"R35-6-20210218","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"R36-6-20210218","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R37-6-20210218","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION Study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"R38-6-20210218","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.tp.0000256179.14038.e2","article-title":"Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.","volume":"83","author":"Kandaswamy","year":"2007","journal-title":"Transplantation"},{"key":"R39-6-20210218","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007890-199001000-00008","article-title":"Proteinuria in cyclosporine-treated renal transplant recipients.","volume":"49","author":"Vathsala","year":"1990","journal-title":"Transplantation"},{"key":"R40-6-20210218","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/ki.1993.187","article-title":"Capillary deposition of C4d complement fragment and early renal graft loss.","volume":"43","author":"Feucht","year":"1993","journal-title":"Kidney Int"},{"key":"R41-6-20210218","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival.","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"key":"R42-6-20210218","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-6143.2008.02462.x","article-title":"Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts.","volume":"9","author":"Mengel","year":"2009","journal-title":"Am J Transplant"},{"key":"R43-6-20210218","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa035588","article-title":"Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.","volume":"349","author":"Sarwal","year":"2003","journal-title":"N Engl J Med"},{"key":"R44-6-20210218","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1600-6143.2005.01050.x","article-title":"Predicting subsequent decline in kidney allograft function from early surveillance biopsies.","volume":"5","author":"Cosio","year":"2005","journal-title":"Am J Transplant"},{"key":"R45-6-20210218","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1681\/ASN.2010010049","article-title":"Fibrosis with inflammation at one year predicts transplant functional decline.","volume":"21","author":"Park","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R46-6-20210218","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/j.1600-6143.2010.03240.x","article-title":"Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure.","volume":"10","author":"Mannon","year":"2010","journal-title":"Am J Transplant"},{"key":"R47-6-20210218","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.","volume":"90","author":"Gaston","year":"2010","journal-title":"Transplantation"},{"key":"R48-6-20210218","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/j.1600-6143.2009.02761.x","article-title":"Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.","volume":"9","author":"Sis","year":"2009","journal-title":"Am J Transplant"},{"key":"R49-6-20210218","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1046\/j.1523-1755.2003.00270.x","article-title":"Disease progression and outcomes in chronic kidney disease and renal transplantation.","volume":"64","author":"Djamali","year":"2003","journal-title":"Kidney Int"},{"key":"R50-6-20210218","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00007890-199102000-00011","article-title":"The variable nature of chronic declines in renal allograft function.","volume":"51","author":"Kasiske","year":"1991","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"R51-6-20210218","first-page":"55","article-title":"Late, not early, events have the greatest impact on kidney transplant failure (abstract).","volume":"11","author":"Gaston","year":"2011","journal-title":"Am J Transplant"},{"key":"R52-6-20210218","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","article-title":"Identifying specific causes of kidney allograft loss.","volume":"9","author":"El-Zoghby","year":"2009","journal-title":"Am J Transplant"},{"key":"R53-6-20210218","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/TP.0b013e3181ff87cd","article-title":"Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.","volume":"90","author":"Larsen","year":"2010","journal-title":"Transplantation"},{"key":"R54-6-20210218","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R55-6-20210218","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"R56-6-20210218","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.","volume":"9","author":"Busque","year":"2009","journal-title":"Am J Transplant"},{"key":"R57-6-20210218","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/TP.0b013e3182145306","article-title":"Novel strategies in immunosuppression: issues in perspective.","volume":"91","author":"Webber","year":"2011","journal-title":"Transplantation"}],"container-title":["Current Opinion in Organ Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOT.0b013e32834c23a7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:26Z","timestamp":1786048166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00075200-201112000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mot.0b013e32834c23a7","relation":{},"ISSN":["1087-2418"],"issn-type":[{"value":"1087-2418","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}